Fig. 4.

Inhibition of cytokine-induced FcγRII expression by RNA or protein synthesis inhibitors. Endothelial cells were treated with 2 μg/ml actinomycin D (Act D), 30 μg/ml cycloheximide (CHX), or puromycine (PMC) for 4 h prior to addition of the cytokines. The binding of 5 μg/ml anti-FcγRII MoAbs was determined after 24 h.